These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 9549180)

  • 1. [Differences in the release of omeprazole in 4 commercial preparations: influence of pH and ionic concentration].
    Navarro MA; Raei N; Torres F; Granero L; García-Zaragoza E; Esplugues JV; Esteban Peris J
    Gastroenterol Hepatol; 1998 Feb; 21(2):63-70. PubMed ID: 9549180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro study on capsule formulations of omeprazole containing enteric coated granules.
    Pandey VP; Phanindrudu A; Manavalan R; Livingston J
    Boll Chim Farm; 2002; 141(6):419-22. PubMed ID: 12577509
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison.
    Mohylyuk V; Yerkhova A; Katynska M; Sirko V; Patel K
    AAPS PharmSciTech; 2021 Jun; 22(5):188. PubMed ID: 34159427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Generic omeprazole delayed-release capsules: in vitro performance evaluations.
    Moore T; Smith A; Ye W; Toler DY; Westenberger BJ; Lionberger R; Raw A; Yu L; Buhse LF
    Drug Dev Ind Pharm; 2009 Aug; 35(8):917-21. PubMed ID: 19555236
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stability of capsules containing omeprazole in enteric coated pellets.
    Palummo M; Cingolani A; Dall L; Volonté MG
    Boll Chim Farm; 2000; 139(3):124-8. PubMed ID: 10961022
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro evaluation of dissolution properties and degradation products of omeprazole in enteric-coated pellets.
    Storpirtis S; Rodrigues D
    Drug Dev Ind Pharm; 1998 Nov; 24(11):1101-7. PubMed ID: 9876567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bioavailability of three brands of omeprazole capsule and their effects on 24 hour intragastric pH in healthy volunteers].
    Dong H
    Zhonghua Nei Ke Za Zhi; 1999 Aug; 38(8):533-6. PubMed ID: 11798692
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dissolution of omeprazole from delayed-release solid oral dosage forms.
    Farinha A; Bica A; Martins JM; Pais JP
    Drug Dev Ind Pharm; 2000 Jul; 26(7):785-90. PubMed ID: 10872100
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development of a bionic system for the simultaneous prediction of the release/absorption characteristics of enteric-coated formulations.
    Liu W; He X; Li Z; Gao X; Ma Y; Xun M; Liu C
    Pharm Res; 2013 Feb; 30(2):596-605. PubMed ID: 23135820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence between omeprazole MUPS 20 mg as tablet and omeprazole MUPS 20 mg as tablet encapsulated in a hard gelatine capsule.
    Schaltenbrand R; Huber R; Cotoraci CA; Mascher H; Potthast H; Hole U
    Int J Clin Pharmacol Ther; 2001 Oct; 39(10):453-9. PubMed ID: 11680670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction of omeprazole with enteric-coated salicylate tablets.
    Nefesoglu FZ; Ayanoglu-Dülger G; Ulusoy NB; Imeryüz N
    Int J Clin Pharmacol Ther; 1998 Oct; 36(10):549-53. PubMed ID: 9799060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro dissolution of proton-pump inhibitor products intended for paediatric and geriatric use in physiological bicarbonate buffer.
    Liu F; Shokrollahi H
    Int J Pharm; 2015 May; 485(1-2):152-9. PubMed ID: 25746736
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of orally administered enteric-coated omeprazole on gastric acid secretion in horses.
    Andrews FM; Doherty TJ; Blackford JT; Nadeau JA; Saxton AM
    Am J Vet Res; 1999 Aug; 60(8):929-31. PubMed ID: 10451198
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative pharmacodynamic study of IY-81149 versus omeprazole in patients with gastroesophageal reflux disease.
    Periclou AP; Goldwater R; Lee SM; Park DW; Kim DY; Cho KD; Boileau F; Jung WT
    Clin Pharmacol Ther; 2000 Sep; 68(3):304-11. PubMed ID: 11014412
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic comparison of omeprazole capsules and a simplified omeprazole suspension.
    Song JC; Quercia RA; Fan C; Tsikouris J; White CM
    Am J Health Syst Pharm; 2001 Apr; 58(8):689-94. PubMed ID: 11329761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of the composition of a fixed dose combination on bioequivalence results.
    Šalandová J; Franc A; Hofmann J; Dumicic A; Kukačková L; Červená T; Beránek J; Srbek J; Repický A; Vladovičová B; Vetchý D
    Int J Pharm; 2018 Jul; 546(1-2):235-246. PubMed ID: 29758343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omeprazole--a new formulation.
    Armstrong D
    Can J Gastroenterol; 1997; 11(8):655-6. PubMed ID: 9459043
    [No Abstract]   [Full Text] [Related]  

  • 18. Dissolution test for liquid formulations of omeprazole enteric-coated products.
    Jang HJ; Kang BC; Shin WG; Lee S
    Ann Pharmacother; 2003 Jan; 37(1):150-1. PubMed ID: 12503954
    [No Abstract]   [Full Text] [Related]  

  • 19. Assessment of the pharmaceutical quality of omeprazole capsule brands marketed in Egypt.
    El-Sayed A; Boraie NA; Ismail FA; El-Khordagui LK; Khalil SA
    East Mediterr Health J; 2007; 13(6):1427-37. PubMed ID: 18341192
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro dissolution and in vivo oral absorption of methylphenidate from a bimodal release formulation in healthy volunteers.
    Wang Y; Lee L; Somma R; Thompson G; Bakhtiar R; Lee J; Rekhi GS; Lau H; Sedek G; Hossain M
    Biopharm Drug Dispos; 2004 Mar; 25(2):91-8. PubMed ID: 14872557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.